The "High Potency Active Pharmaceutical Ingredients Market, by Product, by Manufacturer, by Drug, by Application, and by Region - Global Forecast to 2023-2033" report has been added to ResearchAndMarkets.com's offering.
The high potency active pharmaceutical ingredients market size is estimated to be USD 25.01 billion in 2022 and is expected to witness a CAGR of 6.45% during the forecast period 2023-2033.
Growing applications of HPAPI, growth of targeted therapies, and an increase in the incidence of cancer are some of the factors contributing to the market growth.
Furthermore, rising investment in manufacturing facilities, an increase in R&D for anticancer medications, and the development of novel medications to satisfy the rising demand for the production of active ingredients are other factors supporting the market growth.
However, manufacturing facilities were shut down for safety reasons due to an increase in the frequency of infections among employees expected to hinder the growth.
Rising investment in manufacturing facilities are expected to fuel the market growth during the forecast period. The high potency active pharmaceutical ingredients market involves complicated materials with significant production and manufacturing unit establishment costs. To meet the growing market demand, businesses are investing in the expansion of their manufacturing facilities.
For instance, in April 2022, Cambrex declared the completion of a $50 million expansion and the opening of new, highly effective facilities in the United States.
Segmentation
By Product
The market is segmented into biotech and synthetic. In 2022, the synthetic segment accounted for the highest revenue share during the forecast period due to the relatively low doses, synthetic HPAPIs are more effective therapeutically for a range of diseases. Generic medications are also becoming more widely available on the market as patents on synthetic substances expire. In response to COVID-19, the FDA established the generic medicine programme to ensure that high-quality and reasonably priced drugs are available in the United States. The entire cost of healthcare and the financial strain on patients are reduced by supporting generic products.
The expansion of the biotech category may also be related to high investments in the biotechnology and biopharmaceutical industries. This makes it possible to create innovative molecules that aid in the treatment of diseases like cancer. Pharmaceutical companies are increasingly turning to outside producers due to the high cost of creating biotechnological items and the requirement for highly specialised facilities and qualified staff. The outsourcing of HPAPIs has given suppliers more negotiating power.
For instance, in January 2022, the collaboration between Lonza, BioGeneration Ventures (BGV), and Forbion has been expanded to cover the development and manufacturing of small molecules (biologics). The large molecular biologic portfolio of BGV and Forbion will receive specialised services from Lonza.
By Manufacturer
The market is segmented into outsourced, and in-house. In 2022, the in-house segment accounted for the largest revenue share owing to Key players' product development ambitions indicate that they are strongly focused on internal manufacturing rather than outsourcing.
For instance, advantageous government initiatives like Atmanirbhar Bharat, Pharma Vision 2020, and the Production Linked Incentive Plan are anticipated to generate profitable prospects for the expansion of the pharmaceutical industry as a whole.
Additionally, the outsourced segment is anticipated to have the fastest CAGR during the forecast period due to the market for high-potency APIs is adopting outsourcing at an increasingly rapid rate. Outsourced production lowers the company's risk, resource commitment, and product complexity. Developing nations are also a cost-effective option for outsourcing because they have lower manufacturing costs, which enable businesses to earn bigger profits, which are then anticipated to increase market demand. For instance, in June 2022, another high-potency API (HPAPI) plant has been launched by WuXi STA, a WuXi AppTec subsidiary, at its Changzhou location (Jiangsu, China). To address the rising demand for high-potency API process R&D and production services, the new factory has been added.
By Drug
The market is categorized into generic and innovative. In 2022, the innovative drugs segment accounted for the highest revenue share during the forecast period owing to the increased focus on personalized and precision medicines, such as Antibody-Drug Conjugates (ADCs), the creation of innovative HPAPIs to treat certain patient conditions, making innovation in this field a market driver for the growth of the market.
By Application
The market is segmented into glaucoma, oncology, and hormonal. The oncology segment is accounted to witness the highest revenue share in 2022 owing to the growing prevalence of cancer globally. For instance, according to GLOBOCAN 2020, there were approximately 10.0 million cancer deaths and 19.3 million new cases of cancer in the year 2020. Lung and breast cancers were shown to be the two cancer types that occur the most frequently globally. Key market competitors are increasing their manufacturing capacities to fill gaps in the market caused by the rise in cancer incidence.
For instance, in June 2022, to accommodate the growing demand for cancer therapy components, Merck announced the development of its American HPAPI facility in Verona. Additionally, the hormonal segment is predicted to grow at fastest CAGR during the forecast period.
Regional Markets
In 2022, North America region accounted for the highest revenue in the high potency active pharmaceutical ingredients market during the forecast period owing to the increase in cancer cases, the growth of the infrastructure, and the presence of significant market rivals. For instance, in 2021, there were an estimated 1.9 million new cases of cancer and 608,570 deaths from it in the United States. The region is anticipated to grow as a result of stronger regulatory support, an increase in the prevalence of chronic diseases, and growing consumer demand for fast-acting, highly effective medicines.
Segmentation: High Potency Active Pharmaceutical Ingredients Market Report 2022 - 2033
By Product (Revenue, USD Billion), 2022 - 2033
- Biotech
- Synthetic
By Manufacturer (Revenue, USD Billion), 2022 - 2033
- Outsourced
- In-house
By Drug (Revenue, USD Billion), 2022 - 2033
- Generic
- Innovative
By Application (Revenue, USD Billion), 2022 - 2033
- Glaucoma
- Oncology
- Hormonal
By Region (Revenue, USD Billion), 2022 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Key Topics Covered:
1. Research Methodology
2. Introduction: High Potency Active Pharmaceutical Ingredients
3. Executive Summary
4. Market Dynamics
5. Market Environment Analysis
6. COVID-19 Impact Analysis: High Potency Active Pharmaceutical Ingredients Market
7. Market Analysis by Product
8. Market Analysis by Manufacturer
9. Market Analysis by Drug
10. Market Analysis by Application
11. Regional Market Analysis
12. North America High Potency Active Pharmaceutical Ingredients Market
13. Europe High Potency Active Pharmaceutical Ingredients Market
14. Asia Pacific High Potency Active Pharmaceutical Ingredients Market
15. Latin America High Potency Active Pharmaceutical Ingredients Market
16. MEA High Potency Active Pharmaceutical Ingredients Market
17. Competitor Analysis
18. Company Profiles
19. Conclusion & Recommendations
A selection of companies mentioned in this report includes
- Sun Pharmaceutical Industries Ltd.
- CordenPharma
- Teva Pharmaceutical Industries Ltd.
- Bristol-Myers Squibb Company
- BASF SE
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd. Boehringer Ingelheim International GmbH
- Albany Molecular Research Inc.
- Sanofi
- Lonza
- Dr. Reddy's Laboratories Ltd.
- Cipla Inc.
- Merck & Co. Inc.
- Novartis AG
- CARBOGEN AMCIS AG
For more information about this report visit https://www.researchandmarkets.com/r/6cvsr8
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230331005215/en/
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
